000166657 001__ 166657
000166657 005__ 20240229123233.0
000166657 0247_ $$2doi$$a10.1016/j.breast.2020.12.008
000166657 0247_ $$2pmid$$apmid:33395600
000166657 0247_ $$2ISSN$$a0960-9776
000166657 0247_ $$2ISSN$$a1532-3080
000166657 0247_ $$2altmetric$$aaltmetric:99918474
000166657 037__ $$aDKFZ-2021-00024
000166657 041__ $$aeng
000166657 082__ $$a610
000166657 1001_ $$aSeiffert, Katharina$$b0
000166657 245__ $$aThe effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study.
000166657 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2020
000166657 3367_ $$2DRIVER$$aarticle
000166657 3367_ $$2DataCite$$aOutput Types/Journal article
000166657 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1610448363_1087
000166657 3367_ $$2BibTeX$$aARTICLE
000166657 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166657 3367_ $$00$$2EndNote$$aJournal Article
000166657 520__ $$aThe potential benefit of additional breast cancer screening examinations in moderate risk patients (patients with a history of breast cancer in one or two family members) remains unclear.A large population-based case-control study on breast cancer in postmenopausal women in Germany recruited 2002-2005 (3813 cases and 7341 age-matched controls) was used to assess the association of family history with breast cancer risk. Analysis of family history, participation in screening procedures, and tumor size regarding prognosis in patients was based on follow-up data until 2015.A first degree family history of breast cancer was associated with higher breast cancer risk (OR 1.39, p < 0.001). Patients with a first degree family history of breast cancer were more likely to have had >10 mammograms (MG) (42.7% vs. 24.9%, p < 0.001) and showed a higher rate of imaging-detected tumors (MG or ultrasound) (45.8% vs. 31.9%, p < 0.001). A smaller tumor size at initial diagnosis (below 2 cm) was more likely in patients with a positive family history (OR 1.45, p < 0.001) and a higher number of MG (≥10 MG: OR 2.29). After accounting for tumor characteristics, mammogram regularity (HR 0.72, p < 0.001) and imaging-assisted tumor detection (HR 0.66, p < 0.001) were associated with better overall survival but not with a positive family history.Patients with a positive family history had a higher rate of imaging detected tumors with smaller size at initial diagnosis compared to patients without affected family members. Screening was associated with improved survival after a breast cancer diagnosis, irrespective of a positive family history.
000166657 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000166657 588__ $$aDataset connected to CrossRef, PubMed,
000166657 650_7 $$2Other$$aBreast cancer
000166657 650_7 $$2Other$$aFamilial risk
000166657 650_7 $$2Other$$aMammography
000166657 650_7 $$2Other$$aPrognosis
000166657 650_7 $$2Other$$aScreening
000166657 7001_ $$aThoene, Kathrin$$b1
000166657 7001_ $$aEulenburg, Christine Zu$$b2
000166657 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b3$$udkfz
000166657 7001_ $$aSchmalfeldt, Barbara$$b4
000166657 7001_ $$aBecher, Heiko$$b5
000166657 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b6$$udkfz
000166657 7001_ $$aWitzel, Isabell$$b7
000166657 773__ $$0PERI:(DE-600)2009043-2$$a10.1016/j.breast.2020.12.008$$gVol. 55, p. 98 - 104$$p98 - 104$$tThe breast$$v55$$x0960-9776$$y2020
000166657 909CO $$ooai:inrepo02.dkfz.de:166657$$pVDB
000166657 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000166657 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000166657 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000166657 9141_ $$y2020
000166657 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-09-03$$wger
000166657 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST : 2018$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-03
000166657 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-09-03
000166657 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000166657 980__ $$ajournal
000166657 980__ $$aVDB
000166657 980__ $$aI:(DE-He78)C020-20160331
000166657 980__ $$aUNRESTRICTED